Followers | 800 |
Posts | 118388 |
Boards Moderated | 0 |
Alias Born | 11/20/2004 |
Monday, September 19, 2016 10:25:43 AM
NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, today announced that it has signed an exclusive distribution agreement with Israel-based Rafa Laboratories, Ltd. for distribution of its award-winning cannabinoid chewing gum CanChew.®
Under terms of the agreement, Rafa will submit AXIM® Biotech’s CanChew® to the Israeli Ministry of Health to be registered as a nutraceutical in the Country, and will market and distribute the product throughout Israel beginning in 2017. In addition, once AXIM® Biotech’s patented pharmaceutical chewing gum MedChew Rx™, which is currently in clinical trials for registration as a drug for patients suffering from pain and/or spasticity associated with MS, is approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), Rafa will submit it to be registered as a Rx drug product in Israel, and will market and distribute the product throughout the Country.
“We are pleased to have Rafa as our partner, and our distribution agreement represents an important step to enable expanded market access to our unique, cannabinoid-based products,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies. “Rafa has a 79-year history as a trusted partner to some of the world’s leading pharmaceutical companies, and we believe the Company maintains our goal to have a lasting impact on individuals’ well-being. Distribution agreements such as this one with Rafa are steps forward for AXIM to change the healthcare landscape by introducing our proprietary cannabinoid products to pharmaceutical and retail consumer markets worldwide.”
Recent AXIM News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 04:59:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:29:50 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/21/2023 03:07:21 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/31/2023 08:10:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 05:35:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:11:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM